Premium
Nodular lymphocyte predominant Hodgkin lymphoma: Clincopathological study of 25 cases from J apan with a reappraisal of tissue associated macrophages
Author(s) -
Eladl Ahmed E.,
Satou Akira,
Elsayed Ahmed Ali,
Suzuki Yuka,
ShimizuKohno Kei,
Kato Seiichi,
Tomita Akihiro,
Kinoshita Tomohiro,
Nakamura Shigeo,
Asano Naoko
Publication year - 2015
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.12357
Subject(s) - cd68 , cd163 , medicine , lymphoma , pathology , lymphocyte , b symptoms , hodgkin lymphoma , hodgkin's lymphoma , lymph node , gastroenterology , immunohistochemistry , macrophage , biology , biochemistry , in vitro
Clinicopathological features of 25 nodular lymphocyte predominant Hodgkin lymphoma ( NLPHL ) patients in J apan were analysed. To investigate the clinicopathological significance of tissue associated macrophages ( TAM ) in NLPHL , CD68 and CD163 expression were investigated. The median age at onset was 56 years (range: 6–82 years) with male predominance (64%). All patients presented with lymph node enlargement with predilection for cervical LNs . Seven cases (28%) had mediastinal lesion and four (16%) had extranodal involvement. Most cases (76%) presented with early clinical stages. After median follow up of 44 months, both of overall and progression free survival rates were 95%. The presence of >5% CD68+ TAM in NLPHL was significantly associated with older age at diagnosis (median, 71 vs 52.5 years; P = 0.048), lower hemoglobin level (33.3% vs 0%; P = 0.037) and lower CR rate after initial treatment (42.9% vs 91.7%; P = 0.038). The presence of >5% CD163+ TAM was significantly correlated with presence of B symptoms (40% vs 0%; P = 0.036). In conclusion, NLPHL is rare among Japanese and appears to present at an older age than among Western patients. In our series, the presence of >5% CD68+ TAM in NLPHL was associated with lower CR rate, but with no impact on patients' survival.